As the Canadian market navigates through complex trade developments and anticipates potential central bank rate cuts, investors are keeping a close eye on economic indicators that could influence market volatility. Amidst these broader economic conditions, penny stocks remain an intriguing area for investors seeking growth opportunities at lower price points. Although the term "penny stocks" may seem outdated, these smaller or newer companies can offer significant upside potential when backed by strong financial health and solid fundamentals.
Top 10 Penny Stocks In Canada
| Name | Share Price | Market Cap | Rewards & Risks |
| PetroTal (TSX:TAL) | CA$0.67 | CA$597.17M | ✅ 3 ⚠️ 3 View Analysis > |
| Orezone Gold (TSX:ORE) | CA$1.34 | CA$680.55M | ✅ 4 ⚠️ 2 View Analysis > |
| Dynacor Group (TSX:DNG) | CA$4.53 | CA$190.55M | ✅ 4 ⚠️ 2 View Analysis > |
| Fintech Select (TSXV:FTEC) | CA$0.025 | CA$2.4M | ✅ 2 ⚠️ 3 View Analysis > |
| Findev (TSXV:FDI) | CA$0.44 | CA$12.6M | ✅ 2 ⚠️ 4 View Analysis > |
| Thor Explorations (TSXV:THX) | CA$0.74 | CA$485.67M | ✅ 3 ⚠️ 2 View Analysis > |
| NTG Clarity Networks (TSXV:NCI) | CA$2.24 | CA$100.32M | ✅ 4 ⚠️ 2 View Analysis > |
| Intermap Technologies (TSX:IMP) | CA$2.23 | CA$125.8M | ✅ 3 ⚠️ 2 View Analysis > |
| Hemisphere Energy (TSXV:HME) | CA$1.85 | CA$176.35M | ✅ 3 ⚠️ 1 View Analysis > |
| McChip Resources (TSXV:MCS) | CA$0.95 | CA$5.42M | ✅ 2 ⚠️ 4 View Analysis > |
Click here to see the full list of 880 stocks from our TSX Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
AKITA Drilling (TSX:AKT.A)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: AKITA Drilling Ltd. is an oil and gas drilling contractor operating in Canada and the United States, with a market cap of CA$86.95 million.
Operations: The company's revenue is primarily derived from its Contract Drilling Services segment, which generated CA$212.11 million.
Market Cap: CA$86.95M
AKITA Drilling Ltd. recently reported a strong first quarter with sales of CA$65.09 million, up from CA$46.3 million the previous year, and net income increasing to CA$8.63 million from CA$2.63 million. The company has shown consistent profit growth over the past five years, although recent earnings growth of 63.8% is slightly below its long-term average of 68.6%. AKITA's financial health appears robust with short-term assets exceeding both short and long-term liabilities, while debt levels have decreased significantly over time, enhancing stability in this volatile sector despite low return on equity and interest coverage concerns.
- Take a closer look at AKITA Drilling's potential here in our financial health report.
- Learn about AKITA Drilling's future growth trajectory here.
MediPharm Labs (TSX:LABS)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: MediPharm Labs Corp. is a pharmaceutical company specializing in the production and sale of purified cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products across Canada, Australia, Germany, and internationally with a market cap of CA$33.21 million.
Operations: The company's revenue of CA$43.00 million is generated from the production and sale of cannabis extracts and derivative products.
Market Cap: CA$33.21M
MediPharm Labs Corp. is navigating a challenging landscape, marked by recent legal and activist investor activities. Despite being unprofitable, the company has reduced its losses over the past five years and forecasts revenue growth of 12.82% annually. MediPharm's financial health is supported by sufficient cash reserves exceeding total debt, with short-term assets covering liabilities comfortably. Recent developments include the dismissal of a lawsuit against it and strategic moves like launching cannabis metered dose inhalers in international markets, which could enhance its market position amid ongoing shareholder disputes leading up to its annual meeting on June 16, 2025.
- Click here and access our complete financial health analysis report to understand the dynamics of MediPharm Labs.
- Explore MediPharm Labs' analyst forecasts in our growth report.
Laurion Mineral Exploration (TSXV:LME)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Laurion Mineral Exploration Inc. focuses on acquiring, exploring, and developing mineral properties in Canada with a market cap of CA$82.09 million.
Operations: Laurion Mineral Exploration Inc. has not reported any revenue segments.
Market Cap: CA$82.09M
Laurion Mineral Exploration Inc. is a pre-revenue company focused on advancing its Ishkoday Project with a strategic multi-year diamond drilling program targeting gold-bearing veins and broader mineralized systems. Despite no significant revenue, Laurion maintains a stable cash runway exceeding one year and remains debt-free, highlighting financial prudence. Recent developments include reaffirming strategic partnerships amid global monetary shifts favoring gold as a Tier 1 asset under Basel III regulations. However, the company faces challenges with ongoing losses and auditor concerns about its ability to continue as a going concern, underscoring inherent risks in exploration ventures.
- Dive into the specifics of Laurion Mineral Exploration here with our thorough balance sheet health report.
- Gain insights into Laurion Mineral Exploration's historical outcomes by reviewing our past performance report.
Turning Ideas Into Actions
- Click through to start exploring the rest of the 877 TSX Penny Stocks now.
- Curious About Other Options? AI is about to change healthcare. These 22 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Laurion Mineral Exploration might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com